Literature DB >> 7716451

[Epidemiology of toxoplasmosis in Switzerland: national study of seroprevalence monitored in pregnant women 1990-1991].

P Jacquier1, P Hohlfeld, H Vorkauf, P Zuber.   

Abstract

A national study was performed to assess the seroprevalence of anti-Toxoplasma gondii IgG in pregnant women at the time of delivery. The study was organized between 1990 and 1991 in 23 out of 26 Swiss cantons. 9059 women, corresponding to 11.8% of the annual total of births in those cantons, were included. The global seroprevalence of specific IgG was 46.1% (95% confidence interval: 45.0-47.1%). There was no significant difference in seroprevalence between different cantons after adjustment according to age. At the national level, the seroprevalence was 46.0% for Swiss women and 45.8% for women of other nationality (information on nationality was available only for 8382 persons). The use of a model of linear regression according to age showed that the risk of seroconversion among seronegative women during their 9 months of pregnancy was 1.21%. In addition, a certain number of data were calculated from that value to "simulate" a theoretical situation with absence of specific serological screening during pregnancy at a national level and consequently, absence of appropriate treatment. It was estimated that 548 cases of seroconversion would occur annually during pregnancy. This would lead to 183 congenital transmissions of toxoplasmosis, among which, 75% would be asymptomatic at birth. The number of expected pathologies would be: 40 cases of chorioretinitis with impared vision, 18 cases of cerebral lesions, and 2.7 cases of perinatal death. We observed positive results for specific anti-T. gondii-IgM in 1.7% of persons tested. This result can be the source of medical interpretation difficulties if the serum sample is the first done during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7716451

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr Suppl        ISSN: 0250-5525


  11 in total

1.  Can the common brain parasite, Toxoplasma gondii, influence human culture?

Authors:  Kevin D Lafferty
Journal:  Proc Biol Sci       Date:  2006-11-07       Impact factor: 5.349

2.  Prevalence of IgM and IgG antibodies to Toxoplasma gondii in blood donors in the Czech Republic.

Authors:  V Svobodová; I Literák
Journal:  Eur J Epidemiol       Date:  1998-12       Impact factor: 8.082

3. 

Authors:  P Extermann
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

4. 

Authors:  P Holhlfeld
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

Review 5.  Toxoplasma gondii: from animals to humans.

Authors:  A M Tenter; A R Heckeroth; L M Weiss
Journal:  Int J Parasitol       Date:  2000-11       Impact factor: 3.981

6.  Diagnostic implications of kinetics of immunoglobulin M and A antibody responses to Toxoplasma gondii.

Authors:  M Gorgievski-Hrisoho; D Germann; L Matter
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

7.  Seroprevalence of Toxoplasma gondii in newly diagnosed HIV seropositive patients.

Authors:  Anuja Dutta; Preeti R Mehta; Nayana Ingole
Journal:  Indian J Med Res       Date:  2020-11       Impact factor: 2.375

Review 8.  Pregnancy and susceptibility to infectious diseases.

Authors:  Elisabeth Sappenfield; Denise J Jamieson; Athena P Kourtis
Journal:  Infect Dis Obstet Gynecol       Date:  2013-07-07

9.  Undocumented migrants lack access to pregnancy care and prevention.

Authors:  Hans Wolff; Manuella Epiney; Ana P Lourenco; Michael C Costanza; Jacqueline Delieutraz-Marchand; Nicole Andreoli; Jean-Bernard Dubuisson; Jean-Michel Gaspoz; Olivier Irion
Journal:  BMC Public Health       Date:  2008-03-19       Impact factor: 3.295

10.  High Seroprevalence of Toxoplasma gondii Antibody in HIV/AIDS Individuals from North of Iran.

Authors:  Mohammad Taghi Rahimi; Seif Ali Mahdavi; Behzad Javadian; Rozita Rezaei; Mahmood Moosazadeh; Mehri Khademlou; Seyed Hosein Seyedpour; Abolghasem Syadatpanah
Journal:  Iran J Parasitol       Date:  2015 Oct-Dec       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.